Skip to content

Growth hormone axis

GHRP-2

One of the original growth-hormone secretagogue peptides — real pharmacology, no approved physique indication, and formal FDA compounding safety concerns.

L2PreclinicalExperimental / researchUnclearVery low confidenceLast reviewed 2026-08-23
SC injection· unapprovedNasal· unapproved

Also known as: pralmorelin, growth hormone releasing peptide-2

Evidence passport

Last reviewed 2026-08-23

Evidence level
L2Preclinical
Confidence
Very low confidence
Human efficacy
25/100
Human safety
12/100
Regulatory status
Experimental / research
Development
Unclear
Routes
SC injection· unapprovedNasal· unapproved
Evidence base
Mostly preclinical
Furthest stage
Not established
Source curation
Sources fully curated
Clinical maturity
Historical human pharmacology studies; no approved therapeutic programme

Most of this evidence comes from animals and cells

The supporting research for GHRP-2 is predominantly preclinical (Level 1–2). That is a legitimate starting point for science and a poor basis for personal decisions. Human results are not simply a scaled-up version of mouse results.

Overview

Human evidence25/100
Preclinical evidence50/100
Human safety evidence12/100

Clinical maturity: Historical human pharmacology studies; no approved therapeutic programme

Routes & formulations

Marketed / research routes — never approved

SC injection· unapprovedNasal· unapproved

FDA material describes injectable and nasal marketed products. These are unapproved routes for the marketed claims; their availability is not evidence of efficacy.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

UnclearFurthest stage not established in our curated record

Historical clinical pharmacology research exists; no established current development programme in the curated record.

What it is

A synthetic hexapeptide that stimulates growth hormone release via the ghrelin receptor, part of the first wave of GH secretagogue research.

What people claim

  • Raises growth hormone for muscle gain and fat loss
  • Anti-ageing GH restoration

What the evidence actually says

GHRP-2 genuinely raises GH and IGF-1 — that was established in early human pharmacology studies. What was never established is the part people buy it for: no controlled trials demonstrate body-composition, performance or anti-ageing benefit. A hormone change is a surrogate, not an outcome.

Human evidence

  • Early human pharmacology studies confirming GH release.
  • Published serious adverse event case reports noted by the FDA; case reports signal possible harm but do not by themselves prove causation for every event.
  • No controlled trials supporting physique, performance or anti-ageing claims.

Preclinical evidence

  • Ghrelin-receptor pharmacology and animal GH-axis studies.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • GHSR-1a agonism on pituitary somatotrophs and hypothalamic circuits drives GH pulses.

Safety and unknowns

  • The FDA flags immunogenicity and impurity concerns and cites published serious adverse event case reports for compounded use.
  • Chronic GH-axis stimulation has unresolved long-term safety questions.

Cancer relevance

Theoretical / mechanistic concern only

Sustained IGF-1 elevation is a theoretical proliferation concern shared across the GH axis. No human cancer outcome data exist for GHRP-2 itself.

Regulatory status

Not an FDA-approved medicine. The FDA's compounding safety material flags GHRP-2 across injectable and nasal routes, citing immunogenicity and impurity concerns and published serious adverse event case reports.

Evidence grade

L2PreclinicalVery low confidence

Animal, organoid or tissue studies. Mice are not tiny humans.

What would change our rating?

  • Controlled trials with functional or body-composition endpoints.
  • A modern systematic safety dataset.

References and sources

Sources fully curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

No recorded changes yet. Baseline position set on 2026-08-23.